Evidence map›Paper›PMID 28707730›Full record

ArticleClinical and experimental immunology2017

Complement and contact system activation in acute congestive heart failure patients.

C Suffritti, E Tobaldini, R Schiavon, S Strada, L Maggioni, S Mehta, G Sandrone, E Toschi-Dias, M Cicardi, N Montano

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

C SuffrittiDepartments of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy.ORCID 0000-0002-8872-8842
E TobaldiniDepartment of Internal Medicine, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
R SchiavonInternal Medicine, L. Sacco Hospital, University of Milan, Milan, Italy.
S StradaInternal Medicine, L. Sacco Hospital, University of Milan, Milan, Italy.
L MaggioniDepartments of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy.
S MehtaBiomedical Research and Environmental Sciences, JES Tech, Houston, TX, USA.
G SandroneInternal Medicine, L. Sacco Hospital, University of Milan, Milan, Italy.
E Toschi-DiasHeart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil.
M CicardiDepartments of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy.
N MontanoDepartment of Internal Medicine, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
University of Milan · ITJES Tech (United States) · USUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 ± 2 versus 104 ± 3% of total pooled plasma, P < 0·01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 ± 3 versus 108 ± 4%, P = 0·03). When the sample was stratified according to clinical outcome, C3 (98 ± 3 versus 104 ± 4%, P = 0·03) and sC5b-9 levels (204 ± 10 versus 230 ± 11 ng/ml, P = 0·03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 ± 14 versus 243 ± 14 ng/ml, P = 0·04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.

Indexed as

Complement ActivationAgedAged, 80 and overComplement C3Complement C4Complement Membrane Attack ComplexFemaleHeart FailureHospitalizationHumansKininogensMaleStroke VolumeComplement C3Complement C4Complement Membrane Attack ComplexKininogenscomplement systemcontact systemheart failureimmune systemventricular function

Identifiers

PMID28707730
PMCPMC5629426
OpenAlexW2734414957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.